Bristol-Myers Squibb (BRM) Stock Forecast & Price Target

Compare

19 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BRM Analyst Ratings

Moderate Buy

9 Buy

11 Hold

1 Sell

Based on 21 analysts giving stock ratings to

Bristol-Myers

Squibb

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BRM Stock 12 Month Forecast

Average Price Target

€51.24

▼(-0.22% Downside)

Based on 21 Wall Street analysts offering 12 month price targets for Bristol-Myers Squibb in the last 3 months. The average price target is €51.24 with a high forecast of €63.33 and a low forecast of €33.77. The average price target represents a -0.22% change from the last price of €51.35.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"32":"€32","40":"€40","48":"€48","56":"€56","64":"€64"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":63.32699775,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€63.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":51.2357629796,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€51.24</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.7743988,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€33.77</span>\n  </div></div>","useHTML":true}}],"tickPositions":[32,40,48,56,64],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.02,48.27438444230769,49.52876888461539,50.78315332692308,52.03753776923077,53.29192221153846,54.54630665384615,55.80069109615384,57.05507553846154,58.30945998076923,59.56384442307692,60.81822886538461,62.07261330769231,{"y":63.32699775,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.02,47.34428945996923,47.66857891993846,47.99286837990769,48.31715783987693,48.641447299846156,48.965736759815385,49.290026219784615,49.614315679753844,49.93860513972307,50.26289459969231,50.58718405966154,50.91147351963077,{"y":51.2357629796,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.02,46.001107600000005,44.982215200000006,43.9633228,42.9444304,41.925538,40.906645600000004,39.887753200000006,38.8688608,37.8499684,36.831076,35.8121836,34.7932912,{"y":33.7743988,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":54.4,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.695,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.21,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.26,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.778,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 50, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.238,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.834,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 45, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.404,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.599,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.489,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.881,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 50, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.458,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.02,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€63.33

Average Price Target€51.24

Lowest Price Target€33.77

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Emily Field

Barclays

€63.33

Buy

23.32%

Upside

Initiated

02/19/26

Bristol Myers initiated with an Overweight at BarclaysBristol Myers initiated with an Overweight at Barclays

Matt Phipps

William Blair

Hold

―

Reiterated

02/17/26

Balanced Risk-Reward Keeps Bristol-Myers Squibb Rated Hold as CELMoD Franchise Awaits Key Iberdomide Data

Courtney Breen

Bernstein

€48.97

Hold

-4.63%

Downside

Reiterated

02/10/26

Bristol-Myers Squibb: Solid Near-Term Execution and 2026 EPS Boost from Eliquis, but Limited Long-Term Visibility Supports Hold Rating

Jason Gerberry

Bank of America Securities

€57.42

Buy

11.81%

Upside

Reiterated

02/06/26

Reiterating Buy on Bristol-Myers Squibb: Near-Term Outperformance and Pipeline-Driven Upside Support Higher $68 Target

Seamus Fernandez

Guggenheim

€52.35→€60.79

Buy

18.39%

Upside

Reiterated

02/06/26

Bristol Myers price target raised to $72 from $62 at GuggenheimBristol Myers price target raised to $72 from $62 at Guggenheim

Terence Flynn

Morgan Stanley

€31.24→€33.77

Sell

-34.23%

Downside

Reiterated

02/06/26

Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (NASDAQ: ARWR), Resmed (NYSE: RMD) and Bristol-Myers Squibb (NYSE: BMY)

Geoff Meacham

Citi

€50.66→€54.04

Hold

5.24%

Upside

Reiterated

02/06/26

Bristol Myers price target raised to $64 from $60 at CitiBristol Myers price target raised to $64 from $60 at Citi

Mohit Bansal

Wells Fargo

€46.44→€50.66

Hold

-1.34%

Downside

Reiterated

02/06/26

Bristol Myers price target raised to $60 from $55 at Wells FargoBristol Myers price target raised to $60 from $55 at Wells Fargo

Louise Chen

Scotiabank

€50.66

Hold

-1.34%

Downside

Reiterated

02/06/26

Bristol-Myers Squibb (BMY) Gets a Hold from Scotiabank

Srikripa Devarakonda

Truist Financial

€54.88

Buy

6.88%

Upside

Reiterated

02/05/26

Reiterating Buy on Bristol-Myers Squibb: Milvexian’s Validated FXIa Mechanism and Underappreciated Stroke Prevention Upside Support $65 Target

Evan Seigerman

BMO Capital

€46.44

Hold

-9.56%

Downside

Reiterated

02/05/26

Analysts Conflicted on These Healthcare Names: BridgeBio Pharma (NASDAQ: BBIO), Bristol-Myers Squibb (NYSE: BMY) and Qiagen (NYSE: QGEN)

Asad Haider

Goldman Sachs

€48.13

Hold

-6.27%

Downside

Reiterated

01/29/26

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (NYSE: BMY) and Regeneron (NASDAQ: REGN)

David Amsellem

Piper Sandler

€52.35→€55.73

Buy

8.53%

Upside

Reiterated

01/28/26

Bristol Myers price target raised to $66 from $62 at Piper SandlerBristol Myers price target raised to $66 from $62 at Piper Sandler

Chris Schott

J.P. Morgan

€54.88

Buy

6.88%

Upside

Reiterated

01/28/26

Analysts Are Bullish on These Healthcare Stocks: Bristol-Myers Squibb (BMY), HCA Healthcare (HCA)

Unknown Analyst

Berenberg Bank

Not Ranked

Berenberg Bank

€48.13

Hold

-6.27%

Downside

Reiterated

01/16/26

Bristol-Myers Squibb (BMY) Gets a Hold from Berenberg Bank

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Emily Field

Barclays

€63.33

Buy

23.32%

Upside

Initiated

02/19/26

Bristol Myers initiated with an Overweight at BarclaysBristol Myers initiated with an Overweight at Barclays

Matt Phipps

William Blair

Hold

―

Reiterated

02/17/26

Balanced Risk-Reward Keeps Bristol-Myers Squibb Rated Hold as CELMoD Franchise Awaits Key Iberdomide Data

Courtney Breen

Bernstein

€48.97

Hold

-4.63%

Downside

Reiterated

02/10/26

Bristol-Myers Squibb: Solid Near-Term Execution and 2026 EPS Boost from Eliquis, but Limited Long-Term Visibility Supports Hold Rating

Jason Gerberry

Bank of America Securities

€57.42

Buy

11.81%

Upside

Reiterated

02/06/26

Reiterating Buy on Bristol-Myers Squibb: Near-Term Outperformance and Pipeline-Driven Upside Support Higher $68 Target

Seamus Fernandez

Guggenheim

€52.35→€60.79

Buy

18.39%

Upside

Reiterated

02/06/26

Bristol Myers price target raised to $72 from $62 at GuggenheimBristol Myers price target raised to $72 from $62 at Guggenheim

Terence Flynn

Morgan Stanley

€31.24→€33.77

Sell

-34.23%

Downside

Reiterated

02/06/26

Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (NASDAQ: ARWR), Resmed (NYSE: RMD) and Bristol-Myers Squibb (NYSE: BMY)

Geoff Meacham

Citi

€50.66→€54.04

Hold

5.24%

Upside

Reiterated

02/06/26

Bristol Myers price target raised to $64 from $60 at CitiBristol Myers price target raised to $64 from $60 at Citi

Mohit Bansal

Wells Fargo

€46.44→€50.66

Hold

-1.34%

Downside

Reiterated

02/06/26

Bristol Myers price target raised to $60 from $55 at Wells FargoBristol Myers price target raised to $60 from $55 at Wells Fargo

Louise Chen

Scotiabank

€50.66

Hold

-1.34%

Downside

Reiterated

02/06/26

Bristol-Myers Squibb (BMY) Gets a Hold from Scotiabank

Srikripa Devarakonda

Truist Financial

€54.88

Buy

6.88%

Upside

Reiterated

02/05/26

Reiterating Buy on Bristol-Myers Squibb: Milvexian’s Validated FXIa Mechanism and Underappreciated Stroke Prevention Upside Support $65 Target

Evan Seigerman

BMO Capital

€46.44

Hold

-9.56%

Downside

Reiterated

02/05/26

Analysts Conflicted on These Healthcare Names: BridgeBio Pharma (NASDAQ: BBIO), Bristol-Myers Squibb (NYSE: BMY) and Qiagen (NYSE: QGEN)

Asad Haider

Goldman Sachs

€48.13

Hold

-6.27%

Downside

Reiterated

01/29/26

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (NYSE: BMY) and Regeneron (NASDAQ: REGN)

David Amsellem

Piper Sandler

€52.35→€55.73

Buy

8.53%

Upside

Reiterated

01/28/26

Bristol Myers price target raised to $66 from $62 at Piper SandlerBristol Myers price target raised to $66 from $62 at Piper Sandler

Chris Schott

J.P. Morgan

€54.88

Buy

6.88%

Upside

Reiterated

01/28/26

Analysts Are Bullish on These Healthcare Stocks: Bristol-Myers Squibb (BMY), HCA Healthcare (HCA)

Unknown Analyst

Berenberg Bank

Not Ranked

Berenberg Bank

€48.13

Hold

-6.27%

Downside

Reiterated

01/16/26

Bristol-Myers Squibb (BMY) Gets a Hold from Berenberg Bank

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bristol-Myers Squibb

3 Months

xxx

Success Rate

12/14 ratings generated profit

Average Return

+10.68%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 85.71% of your transactions generating a profit, with an average return of +10.68% per trade.

1 Year

Srikripa DevarakondaTruist Financial

Success Rate

12/14 ratings generated profit

Average Return

+15.49%

reiterated a buy rating 17 days ago

Copying Srikripa Devarakonda's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +15.49% per trade.

2 Years

xxx

Success Rate

14/14 ratings generated profit

Average Return

+28.13%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +28.13% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BRM Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BRM has received 36 Buy Ratings, 35 Hold Ratings, and 4 Sell Ratings. BRM average Analyst price target in the past 3 months is 51.24.

Each month's total comprises the sum of three months' worth of ratings.

BRM Financial Forecast

BRM Earnings Forecast

Next quarter’s earnings estimate for BRM is €1.22 with a range of €1.08 to €1.35. The previous quarter’s EPS was €1.07. BRM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year BRM has Performed in-line its overall industry.

BRM Sales Forecast

Next quarter’s sales forecast for BRM is €9.18B with a range of €8.69B to €9.63B. The previous quarter’s sales results were €10.60B. BRM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year BRM has Performed in-line its overall industry.

BRM Stock Forecast FAQ

What is DE:BRM’s average 12-month price target, according to analysts?

Based on analyst ratings, Bristol-Myers Squibb’s 12-month average price target is 51.24.

What is DE:BRM’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for DE:BRM, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Bristol-Myers Squibb a Buy, Sell or Hold?

Bristol-Myers Squibb has a consensus rating of Moderate Buy, which is based on 9 buy ratings, 11 hold ratings and 1 sell ratings.

What is Bristol-Myers Squibb’s share price target?

The average share price target for Bristol-Myers Squibb is 51.24. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €63.33 ,and the lowest forecast is €33.77. The average share price target represents -0.22% Decrease from the current price of €51.35.

What do analysts say about Bristol-Myers Squibb?

Bristol-Myers Squibb’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of Bristol-Myers Squibb?

To buy shares of DE:BRM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Bristol-Myers Squibb (BRM) Stock Forecast & Price Target

BRM Analyst Ratings

BRM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Bristol-Myers Squibb

BRM Analyst Recommendation Trends

BRM Financial Forecast

BRM Earnings Forecast

BRM Sales Forecast

BRM Stock Forecast FAQ

Detailed List of Analyst Forecasts